MARCO ISLAND, FL, Feb. 14, 2014 – Yesterday, GenCell Biosystems (GenCell) introduced the CLiC LPTM (CLiC) NGS sample preparation system at the Advances in Genome Biology and Technology (AGBT). CLiC is a fully integrated, automated bench-top library preparation system. The platform leverages GenCell’s patented Composite Liquid Cell (CLC) Technology. According to their press release, “the structure mimics natural cell structure by fully encapsulating all reactions in oil, thus eliminating the need for plastic consumables.” Additionally, the protocol-agnostic open architecture can deliver microfluidic miniaturization with as little as 300nL of a starting sample, with input DNA of as little as 1 ng.We stopped by the GenCell suite at AGBT to talk with Robert Roeven, General Manager at GenCell. Roeven gave us some additional information about the platform: CLiC can generate 384 libraries in about 6 hours, with an extra 30-60 minutes to generate an additional 384 libraries (for a total of 768) with only 20 minutes of hands-on time. Of course, these numbers vary depending on the protocol. “The platform has been validated by an early access partner over the past couple of years.” Roeven said. He added that given its high throughput, the platform is clearly targeted towards higher throughput institutions such as genome centers and core facilities.The company is taking orders now, and the platform will be available in the early Summer. The list price for the platform is roughly $300,000.About GenCell Biosystems GenCell Biosystems is a fast-growing biological testing instrumentation and life sciences company based in Limerick, Ireland, with offices in the United States. Founded in 2011, GenCell has quickly become a go-to partner for biotech industry leaders along with academic and public institutions worldwide. From initial contact and feasibility studies through instrument delivery and beyond, GenCell Biosystems takes an extremely collaborative approach with our partners. We believe that a fluid, ongoing discourse leads to the best possible outcomes.---

Authors: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel